Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales ...

Telehealth company Hims & Hers said late Monday in an earnings update that it plans to launch a generic version of Novo ...

HIMS boasts high gross margins (~80%) with no R&D risk, capitalizing on the shift away from traditional pharmacies to ...

Hims & Hers Health exceeded revenue expectations, achieved substantial subscriber growth, and remains undervalued in the ...

Compounded GLP-1s are essentially copies of popular weight loss medications made by manufacturers such as Novo Nordisk and Eli Lilly. Hims & Hers CEO Andrew Dudum said during the company's third ...

Hims & Hers Health (HIMS) shares jumped in extended trading after the company reported better than expected third quarter ...

Hims & Hers Health, Inc. (NYSE:HIMS) has been under pressure this week, with shares declining over 10%, following Eli Lilly's ...

Hims & Hers currently offers compounded GLP-1 weight-loss injections at $199 per month and weight management oral medication ...

Hims & Hers (HIMS) stock price remained on edge even after the fast-growing telehealth company published strong financial ...

Piper Sandler analyst Korinne Wolfmeyer raised the firm’s price target on Hims & Hers to $21 from $18 and keeps a Neutral rating on ...

Truist Financial analyst Jailendra Singh maintained a Hold rating on Hims & Hers Health (HIMS – Research Report) today. The company’s shares closed yesterday at $20.76. According to TipRanks, Singh is ...

Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025.